Revising the role of the androgen receptor in breast cancer
April 2014
in “Journal of Molecular Endocrinology”
TLDR The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
The document from 2014 reviews the role of the androgen receptor (AR) in breast cancer (BC), suggesting that AR positivity is associated with a better prognosis in ER-positive BC and may serve as a therapeutic target, particularly in a subset of triple-negative BCs (TNBCs) known as molecular apocrine. It discusses the potential of AR pathway activation in BC treatment, with clinical trials investigating antiandrogen therapies like bicalutamide and abiraterone acetate. The review also notes the prognostic value of AR, the heterogeneity of BC subtypes, and the importance of molecular profiling in managing BC. It concludes that targeting AR could be a promising strategy for BC patients, especially those with molecular apocrine disease, and highlights the need for further clinical trials to explore AR-targeted therapies.
View this study on jme.bioscientifica.com →
Cited in this study
research Androgen Dependence of Hirsutism, Acne, and Alopecia in Women
Hirsutism is more linked to high androgen levels than acne or hair loss, and a mix of hormonal tests is best for diagnosis; certain treatments can reduce symptoms.
Related
research Revising the role of the androgen receptor in breast cancer
The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.